文献速递乳腺癌

ASCENT 研究生物标志物分析:Trop-2 表达与胚系 BRCA1/2 状态对 sacituzumab govitecan 疗效的影响

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
PubMed 文献 · Ann Oncol · 2021-06-08

ASCENT III 期研究预设探索性生物标志物分析,评估转移性三阴性乳腺癌患者肿瘤 Trop-2 表达水平及胚系 BRCA1/2 突变状态与 sacituzumab govitecan(SG)疗效的关系。结果显示,Trop-2 高/中表达患者中 SG 较化疗在无进展生存期、总生存期和客观缓解率方面数值上更优,且疗效获益与胚系 BRCA1/2 突变状态无关;Trop-2 低表达患者数量少,无法得出确定性结论。

要点

  • Trop-2 高/中表达的经治 mTNBC 患者中,SG 较化疗显示数值上更优的 PFS、OS 和 ORR。
  • SG 的疗效获益在胚系 BRCA1/2 突变阳性和阴性患者中均数值上高于化疗。
  • Trop-2 低表达亚组患者数量少,无法对 SG 在该亚组的获益得出确定性结论。

核心结论

  • SG 使既往接受过治疗的 mTNBC 患者获益,尤其是 Trop-2 高/中表达者,且获益与胚系 BRCA1/2 突变状态无关。
  • Trop-2 低表达患者数量少,无法就该亚组中 SG 的获益得出确定性结论。

研究设计与样本

  • ASCENT 为 III 期随机对照研究,患者按 1:1 随机接受 SG(10 mg/kg 静脉注射,第 1、8 天,每 21 天)或医生选择的单药化疗(卡培他滨、艾日布林、长春瑞滨或吉西他滨)。
  • 纳入既往≥2 线化疗后难治或进展的 mTNBC 患者,其中至少 1 线为转移性治疗。
  • 研究入组时采集活检或手术标本,采用经验证的免疫组化检测和组化评分确定 Trop-2 表达水平,基线收集胚系 BRCA1/2 突变状态。

主要发现

  • 468 例可评估患者中,290 例有 Trop-2 表达数据(SG 组 64%,n=151;TPC 组 60%,n=139),292 例有已知胚系 BRCA1/2 突变状态(SG 组 63%,n=149;TPC 组 61%,n=143)。
  • Trop-2 高、中、低表达患者中,SG 组中位无进展生存期分别为 6.9、5.6、2.7 个月,TPC 组分别为 2.5、2.2、1.6 个月。
  • Trop-2 高、中、低表达患者中,SG 组中位总生存期分别为 14.2、14.9、9.3 个月,TPC 组分别为 6.9、6.9、7.6 个月。
  • Trop-2 高、中、低表达患者中,SG 组客观缓解率分别为 44%、38%、22%,TPC 组分别为 1%、11%、6%。
  • 无论胚系 BRCA1/2 突变状态如何,SG 较 TPC 的疗效结局在数值上更高。

临床怎么用

  • 对于既往接受过治疗的 mTNBC 患者,SG 的疗效获益在 Trop-2 高/中表达者中较为明显,且不受胚系 BRCA1/2 突变状态限制。
  • Trop-2 低表达患者中 SG 的获益尚不确定,临床决策需个体化权衡。

局限性

  • Trop-2 低表达亚组患者数量少,无法得出确定性结论。
  • 该分析为预设探索性生物标志物分析,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The pivotal phase III ASCENT trial demonstrated improved survival outcomes associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti-Trop-2) antibody-drug conjugate linked with the topoisomerase-inhibitor SN-38, over single-agent chemotherapy treatment of physician's choice (TPC) in previously treated metastatic triple-negative breast cancer (mTNBC). This prespecified, exploratory biomarker analysis from the ASCENT trial evaluates the association between tumor Trop-2 expression and germline BRCA1/2 mutation status with clinical outcomes. PATIENTS AND METHODS: Patients with mTNBC refractory to or progressing after two or more prior chemotherapies, with one or more in the metastatic setting, were randomized to receive SG (10 mg/kg intravenously days 1 and 8, every 21 days) or TPC (capecitabine, eribulin, vinorelbine, or gemcitabine) until disease progression/unacceptable toxicity. Biopsy or surgical specimens were collected at study entry to determine Trop-2 expression level using a validated immunohistochemistry assay and histochemical scoring. Germline BRCA1/2 mutation status was collected at baseline. RESULTS: Of 468 assessable patients, 290 had Trop-2 expression data [64% (n = 151 SG) versus 60% (n = 139 TPC)] and 292 had known BRCA1/2 mutation status [63% (n = 149 SG) versus 61% (n = 143 TPC)]. Median progression-free survival in SG- versus TPC-treated patients was 6.9, 5.6, and 2.7 months versus 2.5, 2.2, and 1.6 months for high, medium, and low Trop-2 expression, respectively. Median overall survival (14.2, 14.9, and 9.3 months versus 6.9, 6.9, and 7.6 months) and objective response rates (44%, 38%, and 22% versus 1%, 11%, and 6%) were numerically higher with SG versus TPC in patients with high, medium, and low Trop-2 expression, respectively. Efficacy outcomes were numerically higher with SG versus TPC in patients with and without germline BRCA1/2 mutations. CONCLUSIONS: SG benefits patients with previously treated mTNBC expressing high/medium Trop-2 compared with standard-of-care chemotherapy and regardless of germline BRCA1/2 mutation status. The small number of patients with low Trop-2 expression precludes definitive conclusions on the benefit of SG in this subgroup.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021. PMID: 34116144. doi:10.1016/j.annonc.2021.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。